ABOS Stock Forecast: Acumen Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.19
−0.52% on the day

The median 12-month analyst price target for Acumen Pharmaceuticals, Inc. is $1. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 42 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$14.0M
Ticker Nerd rank
42/ 100
Median analyst target
$1.00
Analysts covering
6
Revenue$0.0
Operating income−$32.6M
Net income−$32.7M
Free cash flow−$18.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.3%
1M
−90.5%
YTD
−90.9%
1Y
−87.7%
From 52W high
−94.3%
From 52W low
0.0%
$0.19
$3.37
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Acumen Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
42/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
87
Accruals
83
Issuance
65
Momentum
33
Revisions
27
Quality
21
Volatility
20
Value
11

Growth (87): Sales and profits are climbing, and climbing faster than before.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ABOS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABOS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00Jan 26Apr 26Jul 26Oct 26ABOSHigh $1.00Median $1.00Low $1.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
1
Buy
3
Hold
2
Sell
$1.00
Low
$1.00
Median
$1.00
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
2 Nov 2026BTIGMaintainsBuy$8.00 → $1.00
30 Oct 2026CitigroupDowngradeNeutral$5.00 → $1.00
16 Sept 2026BTIGReiteratesBuy$8.00
15 Sept 2026CitigroupMaintainsBuy$4.00 → $5.00
26 Mar 2026BTIGReiteratesBuy$8.00
16 Mar 2026BTIGMaintainsBuy—
27 Jan 2026BTIGMaintainsBuy—
18 Nov 2025B of A SecuritiesMaintainsBuy—
25 Aug 2025B of A SecuritiesMaintainsBuy—
17 June 2025CitigroupInitiatesBuy—
28 Mar 2025HC Wainwright & Co.MaintainsBuy—
28 Mar 2025UBSMaintainsBuy—
13 Nov 2024HC Wainwright & Co.ReiteratesBuy—
3 Oct 2024HC Wainwright & Co.ReiteratesBuy—
15 Aug 2024UBSMaintainsBuy—
14 Aug 2024HC Wainwright & Co.ReiteratesBuy—
25 July 2024CitigroupInitiatesBuy—
15 May 2024HC Wainwright & Co.ReiteratesBuy—
31 Mar 2024UBSMaintainsBuy—
27 Mar 2024HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ABOS.

Market Radar

This page is one stock. Monday covers all of them.

ABOS appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ABOS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Acumen Pharmaceuticals, Inc. returned −87.7% against +6.9% for the S&P 500, dividends included.

ABOS vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150200Jan 26Apr 26Jul 26Oct 26ABOSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ABOS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.4×

Cheaper than 89% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−162.7%

Higher than 9% of US stocks

Return on assets
−57.5%

Higher than 7% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Acumen Pharmaceuticals, Inc. has a market value of $14.0M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$105.0M.

  • Free cash flow in the twelve months to 30 June 2026: −$91.8M.

  • Acumen Pharmaceuticals, Inc. spent $149K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 72.3M.

  • Acumen Pharmaceuticals, Inc. employs 60 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ABOS and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ABOSAcumen Pharmaceuticals, Inc.$14.0M42
ESLAEstrella Immunopharma, Inc.$13.5M26
PLURPluri, Inc.$13.5M17
NCELNewCelX Ltd.$13.6M4
ACTUActuate Therapeutics, Inc.$13.6M39
BYSIBeyondSpring, Inc.$13.7M11
TVRDTvardi Therapeutics, Inc.$13.2M30

Take a look at ABOS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Acumen Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ABOS

What is the ABOS stock price forecast for 2026-2027?

The median 12-month analyst price target for Acumen Pharmaceuticals, Inc. is $1. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABOS stock a buy right now?

Of the 6 analysts covering Acumen Pharmaceuticals, Inc., 1 rate it a Buy, 3 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Acumen Pharmaceuticals, Inc. 42 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABOS?

As at 21 Nov 2026, Acumen Pharmaceuticals, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).

Will ABOS stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts is $1, and Ticker Nerd's factor model ranks Acumen Pharmaceuticals, Inc. 42 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABOS stock forecast for 2030?

No analyst covering Acumen Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABOS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1 to $1 over the next 12 months.

How has ABOS stock performed over the past year?

Acumen Pharmaceuticals, Inc. returned -87.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Acumen Pharmaceuticals, Inc. do?

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology.

Company

About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology. Acumen’s work is aimed at disease-modifying treatment approaches rather than symptom management, with its research and clinical programs concentrated on early symptomatic and mild Alzheimer’s disease. Headquartered in Newton, Massachusetts, Acumen Pharmaceuticals operates within the neuroscience and biotechnology sectors, where it plays a specialized role in advancing antibody-based therapies and diagnostics for neurodegenerative disease.

CEO Mr. Daniel J. O'Connell M.B.A. · 60 employees · United States · https://acumenpharm.com